Wall Street firms are responding today to Sagent Pharmaceuticals' (SGNT -2.6%) revised outlook yesterday, which took the shares down over 25% during the trading session. RBC cut the shares to Sector Perform on the news, citing a lack of earnings visibility over the near term, while Needham, cut its price target to $20 from $25, saying the company "remains its own worst enemy" when it comes to managing estimates and maintaining management's credibility.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs